^
Association details:
| Biomarker: | ACVR1-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
Published date:
11/25/2020
Excerpt:
In total, 3787 NSCLC samples were analyzed....five patients harboring genomic-positive but RNA and protein–negative ALK or ROS1 fusion who received crizotinib had PD within 1 to 3 months of therapy
DOI:
10.1016/j.jtho.2020.10.156
